Mifepristone Remains Available by Mail as FDA Launches Six-Month Review

On April 7, 2026, U.S. District Judge David Joseph — a Trump appointee in Lafayette, Louisiana — issued a ruling that satisfied no one completely. He declined to block the mailing of mifepristone, the drug used in roughly 63% of all U.S. abortions, but told the FDA it had six months to finish reviewing the regulations that make mail delivery possible [1]. If the agency fails to act, the judge warned, "the Court's analysis — and the weight accorded to these factors — will inevitably change" [2].

The ruling keeps mifepristone available by mail for now. But it places the drug's distribution framework on a countdown clock, with the FDA under simultaneous pressure from Republican state attorneys general seeking tighter restrictions and Democratic attorneys general demanding looser ones. The stakes extend to an estimated 91,000 patients per year in states with total abortion bans who received the drug by telehealth prescription in 2025 [3].

How Mail-Order Mifepristone Became the Default

The FDA approved mifepristone (brand name Mifeprex) in 2000, initially restricting its use to the first seven weeks of pregnancy and requiring in-person dispensing under a Risk Evaluation and Mitigation Strategy, or REMS — a set of conditions the FDA can impose on drugs it considers safe and effective but that carry specific risks requiring managed distribution [4]. Over the next two decades, the agency gradually loosened those conditions: in 2016, it extended the gestational limit to 10 weeks and reduced the number of required clinic visits; in January 2023, it adopted a revised REMS allowing certified pharmacies to dispense mifepristone by mail [4].

That 2023 change transformed the landscape. By the end of 2024, one in four U.S. abortions were accessed via telehealth — a fivefold increase over two years [5]. The Guttmacher Institute, a reproductive health research organization, reported in March 2026 that approximately 1,126,000 abortions were provided by clinicians in the U.S. in 2025, essentially unchanged from 2024 [3]. But the method of delivery shifted dramatically: for the first time, more women in the 13 states with total abortion bans obtained pills through telehealth than traveled to other states for in-person care [3].

Source: Guttmacher Institute / KFF

Data as of Mar 19, 2026CSV

Medication abortion now accounts for roughly 65% of all U.S. abortions, up from 36% in 2011 [6]. The median cost of a medication abortion through a virtual clinic is $150, compared to $563 at a brick-and-mortar facility [6].

The Lawsuit: Louisiana v. FDA

The case before Judge Joseph, State of Louisiana v. U.S. Food and Drug Administration, was brought by Louisiana Attorney General Liz Murrill, with an individual co-plaintiff, Rosalie Markezich. Drug manufacturers GenBioPro and Danco Laboratories intervened on the FDA's side [2].

Murrill argued that the state "suffers irreparable harm every day" the 2023 REMS remains in effect [1]. Judge Joseph acknowledged that the plaintiffs are "likely to succeed on the merits" but granted the government's request to hold the case while the FDA conducts its review [2]. His reasoning: "Ultimately it is FDA, not this Court, that possesses the expertise to evaluate scientific and make public health judgments" [2].

Mary Ziegler, a law professor at UC Davis who studies the legal history of abortion, told NPR the ruling reflects internal Republican divisions: "We're seeing a kind of civil war between Republicans about how quickly and how far to go" [2]. Murrill has said she plans to appeal to the Fifth Circuit [1].

The Legal Backdrop: What Courts Have Already Said

The current Louisiana case follows the Supreme Court's unanimous ruling in FDA v. Alliance for Hippocratic Medicine in June 2024. Writing for all nine justices, Justice Brett Kavanaugh held that the anti-abortion medical organizations challenging the FDA's mifepristone regulations lacked Article III standing — the constitutional requirement that plaintiffs demonstrate concrete, personal injury — because they neither prescribe nor use the drug [7][8].

That ruling did not reach the merits of whether the FDA's 2023 REMS changes were scientifically sound. It dismissed the case on procedural grounds, leaving the underlying regulatory questions unresolved [7]. The Louisiana lawsuit, brought by a state rather than a private organization, is designed to overcome the standing problem that defeated the Alliance for Hippocratic Medicine.

The legal authority at issue is the FDA's power under the Federal Food, Drug, and Cosmetic Act to set REMS conditions for approved drugs. The central question is whether the FDA has discretion to determine that mail dispensing is safe enough, or whether the 2023 changes exceeded its statutory authority [9]. A separate legal cloud hangs over the entire framework: the Comstock Act, an 1873 anti-vice statute that arguably prohibits mailing abortion drugs nationally, which some legal scholars and Republican officials have argued could be enforced regardless of FDA regulations [6].

Who Petitioned the FDA, and What Evidence Did They Submit?

According to the UCLA Law Mifepristone Litigation and Federal Action Tracker, seven citizen petitions have been filed with the FDA since January 1, 2025, six of which remain open [10].

On the side of expanding access: the American College of Obstetricians and Gynecologists (ACOG), the Society of Family Planning, and the Society for Maternal-Fetal Medicine petitioned the FDA on January 31, 2025, to eliminate the REMS for mifepristone entirely [10]. On June 5, 2025, the attorneys general of California, Massachusetts, New York, and New Jersey filed their own petition to eliminate or stop enforcing the REMS restrictions [11]. Colorado Attorney General Phil Weiser followed on August 20, 2025, calling the restrictions "burdensome" [10].

On the restrictive side: the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG) petitioned on January 7, 2025, urging the FDA to prohibit telehealth prescribing and require in-person follow-up with ultrasounds [10].

HHS Secretary Robert F. Kennedy Jr. testified that he ordered FDA administrator Martin A. Makary to conduct a "complete review" of mifepristone regulations [12]. The scope and timeline of that review are what Judge Joseph's six-month deadline now governs.

The Safety Evidence: What the Data Actually Shows

The core factual dispute is whether mail-dispensed mifepristone is as safe as clinic-dispensed mifepristone.

A prospective study published in Nature Medicine tracked outcomes across multiple telehealth abortion providers and found that 99.8% of abortions were not followed by serious adverse events. The serious adverse event rate was 0.25%, with no differences between synchronous (video) and asynchronous (text-based) models of care. The authors concluded the results were "similar to published rates of in-person medication abortion care" [13].

A separate study of more than 6,000 patients from three telehealth providers, reported by NPR, found a 99.7% rate of no serious adverse events and a 97.7% rate of successful pregnancy termination without additional follow-up [14]. KFF, a nonpartisan health policy research organization, reports an overall major complication rate of 0.4% and a mortality rate of less than 0.001% (0.00064%) for medication abortion [6].

A study published in Contemporary OB/GYN compared outcomes directly: complete abortion without additional treatment occurred in 94.1% of in-person cases, 95.1% of no-test mail cases, and 96.5% of no-test pickup cases [15].

Source: Guttmacher Institute

Data as of Mar 19, 2026CSV

The Steelman Case Against Mail Dispensing

Physicians and researchers who oppose mail dispensing without mandatory in-person screening make a specific clinical argument: that remote prescribing can miss contraindications that require physical examination or ultrasound to detect.

Mifepristone is contraindicated for confirmed or suspected ectopic pregnancy — a pregnancy that implants outside the uterus, which the drug cannot treat and which, left undiagnosed, can cause life-threatening internal hemorrhage [16]. It is also contraindicated for patients with chronic adrenal failure, bleeding disorders, an IUD still in place, and inherited porphyria [16].

ACOG's clinical guidance states that ultrasonography is needed when gestational dating cannot be confirmed clinically or when risk factors for ectopic pregnancy are present. But for patients with regular menstrual cycles, a certain last menstrual period within the prior 56 days, and no ectopic risk factors, ACOG says clinical or ultrasound examination is "not necessary" before medication abortion [17].

AAPLOG and allied critics argue that self-reported menstrual history is insufficient to screen for ectopic pregnancy, which occurs in an estimated 1-2% of all pregnancies [10]. They contend that even a small miss rate, applied across hundreds of thousands of prescriptions annually, could produce a meaningful number of undiagnosed ectopic pregnancies. The Ethics & Public Policy Center published an analysis of insurance claims data suggesting higher adverse event rates than clinical studies report, though the reproductive health research group ANSIRH has published a rebuttal disputing the methodology [18].

The counter-argument, supported by ACOG and the Society of Family Planning, is that ectopic pregnancies typically present with symptoms (pain, bleeding) that prompt emergency evaluation regardless of how the abortion medication was prescribed, and that requiring universal ultrasound screening before medication abortion would create barriers that cause more harm than the rare missed ectopic [17].

How the U.S. Compares Internationally

Mifepristone has been approved in nearly 100 countries worldwide [19]. The United States is an outlier in maintaining a REMS — essentially a restricted distribution system — for the drug.

France approved mifepristone in 1988, the first country to do so. The United Kingdom followed in 1991, initially restricting administration to clinical settings but permanently extending home use after a temporary COVID-era policy change. Canada did not approve mifepristone until 2017, but then took a different regulatory path: it removed all restrictions so the drug could be prescribed and dispensed as a normal medication, with no equivalent of the U.S. REMS system. Australia approved the drug in 2012 and requires prescribing physicians to complete online certification training [19][20].

Source: Guttmacher Institute

Data as of Jul 1, 2023CSV

In Canada, a study published in the New England Journal of Medicine examined outcomes after mifepristone was reclassified as a normal prescription medication — a move that eliminated mandatory in-person dispensing. The study found no increase in adverse events following the regulatory change [20].

Sweden permits midwives, not just physicians, to administer both mifepristone and misoprostol. No country with comparable healthcare infrastructure to the U.S. maintains restrictions as extensive as the American REMS [19].

The gestational age limits vary modestly: France and the UK permit medication abortion up to 9-10 weeks, while the U.S. REMS allows use up to 10 weeks (70 days) [4].

Shield Laws, Preemption, and the Enforcement Gap

Eight states — California, Colorado, Maine, Massachusetts, New York, Rhode Island, Vermont, and Washington — have enacted shield laws that protect providers who prescribe and mail abortion medication to patients in states where the procedure is banned [6]. KFF Health News reported that an average of 7,700 people per month in states with total or six-week bans received mailed mifepristone and misoprostol from out-of-state shield-law providers [21].

These laws are already being tested. In December 2024, the Texas Attorney General filed a lawsuit against a New York physician for mailing abortion pills into Texas. The following month, a Louisiana grand jury indicted the same physician — the first criminal prosecution of its kind [22].

The preemption question is unresolved: if the FDA tightens its REMS to restrict or eliminate mail dispensing, does federal regulatory action override state shield laws that specifically authorize it? Legal analysis from DLA Piper notes that federal drug regulation generally occupies the field, meaning FDA restrictions would likely preempt state laws attempting to authorize distribution methods the FDA has prohibited [23]. But shield laws that protect providers from prosecution under other states' criminal abortion bans operate in a different legal space — they address interstate enforcement, not drug regulation — and might survive federal regulatory changes [23].

The practical effect of an FDA restriction would nonetheless be significant. If mail dispensing is no longer authorized under the REMS, shield-law providers would lose their legal basis for shipping the drug, regardless of whether the shield law itself is preempted. The estimated 91,000 patients per year in ban states who currently receive mifepristone by telehealth would need to travel to a state with in-clinic access or find an alternative [3].

What Happens If Mail Access Ends

Research published in PMC identified 1,091 abortion providers and Planned Parenthood clinics in the United States. Currently, 65.3% of reproductive-age women live within 30 minutes of a clinic, and 88.9% within 90 minutes [24]. But those figures are national averages. In states with total bans, in-clinic mifepristone dispensing is effectively zero. Patients who lose mail access would face travel distances that vary by geography: those in Texas border regions might reach New Mexico clinics within a few hours, while patients in Mississippi or Louisiana face longer trips to Illinois or other access states [24].

KFF reports that 34 states have some form of ban or restriction on medication abortion provision, and 19 states maintain in-person dispensing requirements that contradict the FDA's 2021 removal of such requirements [25]. Nine states — Arizona, Arkansas, Florida, Indiana, Kentucky, Oklahoma, South Carolina, Texas, and West Virginia — explicitly ban telehealth for medication abortion [6].

The dose-response relationship between distance and access is stark: women living 120 or more miles from a provider have abortion rates one-fifth of those living within 5 miles [24].

The Six-Month Clock

The FDA now operates under Judge Joseph's implicit deadline. If the agency completes its review and maintains the current REMS, Louisiana and its allies will challenge that decision in court. If it tightens restrictions, shield-law states and reproductive rights organizations will do the same. If it does nothing, the judge has signaled the judicial calculus will shift against the government.

Planned Parenthood President Alexis McGill Johnson characterized the situation bluntly: "From the courts to the Trump administration to state legislatures...mifepristone and abortion access are very much still under attack" [2].

The review unfolds against a backdrop of seven pending citizen petitions, an HHS Secretary who ordered a "complete review" of the drug's regulations, and a Congress that has shown no appetite for legislative action in either direction. The outcome will directly affect the roughly 710,000 Americans who obtain medication abortions each year — and the 91,000 in ban states for whom the mailbox has become the primary point of access [3][6].